Keros Therapeutics(KROS) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Keros Therapeutics Reports Second Quarter 2024 Financial Results LEXINGTON, Mass., August 7, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ...